FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer

Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Assent, when appropriate, will be obtained per institutional guidelines * Age: \>= 18 years * Eastern Cooperative Oncology Group (ECOG) =\< 1 * Life expectancy \>= 3 months * Patients should have a pathologically proven diagnosis of colorectal adenocarcinoma * Histological or cytological confirmed microsatellite stable (MSS) adenocarcinoma of colon or rectum. Microsatellite status should be performed per local standard of practice (immunohistochemistry \[IHC\] and or polymerase chain reaction \[PCR\], or next-generation sequencing, the presence of POLE mutations will be collected if available through next-generation sequencing) * Patients should have measurable metastatic disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guidelines * Patients should not have a history of perforations or fistulas * For the safety cohorts (phase I): Metastatic colorectal cancer with 0 to 2 prior lines of therapy prior to enrollment on study and without prior progression within 3 months from last dose of oxaliplatin, in the event of prior oxaliplatin exposure. Evidence of radiographic progression after last treatment before enrollment should be documented * Patients with prior FOLFOX therapy should not have required dose modifications and should not have experienced unacceptable toxicities * Patients with other prior 5-FU-based therapies should not have …